NO955352L - Metylfosforsyreester, fremgangsmåte for fremstilling samt anvendelse - Google Patents

Metylfosforsyreester, fremgangsmåte for fremstilling samt anvendelse

Info

Publication number
NO955352L
NO955352L NO955352A NO955352A NO955352L NO 955352 L NO955352 L NO 955352L NO 955352 A NO955352 A NO 955352A NO 955352 A NO955352 A NO 955352A NO 955352 L NO955352 L NO 955352L
Authority
NO
Norway
Prior art keywords
preparation
pct
acid ester
phosphoric acid
methyl phosphoric
Prior art date
Application number
NO955352A
Other languages
English (en)
Other versions
NO955352D0 (no
NO319860B1 (no
Inventor
Eugen Uhlmann
Chris Meier
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO955352D0 publication Critical patent/NO955352D0/no
Publication of NO955352L publication Critical patent/NO955352L/no
Publication of NO319860B1 publication Critical patent/NO319860B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
NO19955352A 1993-07-01 1995-12-29 Metylfosfonsyre-ester, fremgangsmate for fremstilling, legemiddel samt anvendelse NO319860B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4321946A DE4321946A1 (de) 1993-07-01 1993-07-01 Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
PCT/EP1994/002121 WO1995001363A1 (de) 1993-07-01 1994-06-29 Methylphosphonsäureester, verfahren zu deren herstellung und deren verwendung

Publications (3)

Publication Number Publication Date
NO955352D0 NO955352D0 (no) 1995-12-29
NO955352L true NO955352L (no) 1996-02-14
NO319860B1 NO319860B1 (no) 2005-09-26

Family

ID=6491730

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19955352A NO319860B1 (no) 1993-07-01 1995-12-29 Metylfosfonsyre-ester, fremgangsmate for fremstilling, legemiddel samt anvendelse

Country Status (13)

Country Link
US (1) US6028182A (no)
EP (1) EP0707591B1 (no)
JP (1) JP3831407B2 (no)
AT (1) ATE206130T1 (no)
AU (1) AU698928B2 (no)
CA (1) CA2165971C (no)
DE (2) DE4321946A1 (no)
DK (1) DK0707591T3 (no)
ES (1) ES2165391T3 (no)
FI (1) FI115399B (no)
NO (1) NO319860B1 (no)
PT (1) PT707591E (no)
WO (1) WO1995001363A1 (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
DE4331670A1 (de) * 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
DE4338704A1 (de) 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
DE19502912A1 (de) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
PT739898E (pt) * 1995-03-13 2002-03-28 Aventis Pharma Gmbh Mono-esteres de acidos fosfonucleicos processo para a sua preparacao e sua utilizacao
US5821354A (en) * 1996-11-26 1998-10-13 Angiogene Inc. Radiolabeled DNA oligonucleotide and method of preparation
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
ATE342911T1 (de) * 1996-12-24 2006-11-15 Sirna Therapeutics Inc Synthese von nukleosiden und polynukleotiden
EP2204186B1 (en) 1999-02-17 2016-04-06 CSL Limited Immunogenic complexes and methods relating thereto
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
WO2002066092A2 (en) * 2001-02-23 2002-08-29 Angiogene Inc. Drug eluting device for treating vascular diseases
GB0110732D0 (en) * 2001-05-02 2001-06-27 Psl Technology Ltd Apparatus and method
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
KR20050089799A (ko) 2002-10-29 2005-09-08 콜리 파마슈티칼 그룹, 리미티드 C형 간염 바이러스 감염의 치료에 있어 CpG올리고뉴클레오티드의 용도
EP1720568A2 (en) 2004-02-19 2006-11-15 Coley Pharmaceutical Group, Inc. Immunostimulatory viral rna oligonucleotides
WO2007026190A2 (en) 2004-07-18 2007-03-08 Csl Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
JP5473336B2 (ja) 2006-02-15 2014-04-16 アディウタイド・ファーマスーティカルズ・ゲーエムベーハー オリゴヌクレオチドの処方に関する組成物および方法
CN101517082B (zh) 2006-09-27 2014-01-22 科勒制药有限责任公司 具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
CN101678098A (zh) * 2007-05-17 2010-03-24 科勒制药集团公司 具有免疫刺激效力的a类寡核苷酸
CN101820908A (zh) 2007-10-09 2010-09-01 科利制药公司 包含改性糖部分的免疫刺激寡核苷酸类似物
EP2306986B1 (en) * 2008-06-26 2018-03-21 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
CA2745096C (en) 2008-12-09 2013-11-05 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
PE20110891A1 (es) 2008-12-09 2011-12-23 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige
RU2518291C2 (ru) 2009-07-30 2014-06-10 Пфайзер Вэксинс ЭлЭлСи Антигенные tau-пептиды и их применения
ES2683316T3 (es) 2010-05-28 2018-09-26 Zoetis Belgium S.A. Vacunas que comprenden colesterol y CpG como únicas moléculas transportadoras de adyuvante
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
PL2844282T3 (pl) 2012-05-04 2019-11-29 Pfizer Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
CN107428813B (zh) 2014-12-31 2021-08-03 查克美特制药公司 组合肿瘤免疫疗法
EP3752194A4 (en) 2018-02-13 2022-03-16 Checkmate Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY
KR102890791B1 (ko) 2018-04-09 2025-11-24 체크메이트 파마슈티칼스, 인크. 바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장
US20240189410A1 (en) 2022-12-13 2024-06-13 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025238502A1 (en) 2024-05-14 2025-11-20 Pfizer Inc. Aluminum adjuvant nanoparticles, methods of manufacture, and uses thereof
WO2025257712A1 (en) 2024-06-12 2025-12-18 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010140A1 (en) * 1991-11-21 1993-05-27 Pharmagenics, Inc. Oligonucleotides having modified anionic moieties

Also Published As

Publication number Publication date
DK0707591T3 (da) 2002-01-21
US6028182A (en) 2000-02-22
FI956341A0 (fi) 1995-12-29
PT707591E (pt) 2002-03-28
NO955352D0 (no) 1995-12-29
EP0707591A1 (de) 1996-04-24
NO319860B1 (no) 2005-09-26
ES2165391T3 (es) 2002-03-16
FI956341L (fi) 1996-02-19
AU698928B2 (en) 1998-11-12
AU7073594A (en) 1995-01-24
EP0707591B1 (de) 2001-09-26
JPH08512039A (ja) 1996-12-17
ATE206130T1 (de) 2001-10-15
DE59409880D1 (de) 2001-10-31
CA2165971A1 (en) 1995-01-12
DE4321946A1 (de) 1995-01-12
JP3831407B2 (ja) 2006-10-11
FI115399B (fi) 2005-04-29
CA2165971C (en) 2006-05-30
WO1995001363A1 (de) 1995-01-12

Similar Documents

Publication Publication Date Title
NO955352L (no) Metylfosforsyreester, fremgangsmåte for fremstilling samt anvendelse
AU699480B2 (en) 2,2-Dichloroalkane carboxylic acids, processes for their production and pharmaceutical agents containing these
NO308794B1 (no) Farmakologisk aktive pyridin-derivater, preparater inneholdende forbindelsene samt forbindelsenes anvendelse
HU9603592D0 (en) Aryl-sulfonamido-hydroxamic acids of matrix-metalloproteinase-inhibiting activity
EP0948327A4 (en) ANTIDIABETIC AGENTS
IT1270260B (it) Derivati dell'acido fosfonico ad attivita' inibitrice delle metallopeptidasi
WO2000071516A3 (en) INHIBITORS OF FACTOR Xa
ATE181237T1 (de) Substituierte cyclohexan-derivate zur behandlung von krankheiten
WO2001091738A3 (en) Naaladase inhibitors for treating amyotrophic lateral sclerosis
KR0148213B1 (en) Phenyla lkan(en)oic acid and pharmaceutical composition comprising the same
CA2094806A1 (en) Aminosulfonyl urea acat inhibitors
AU686197B2 (en) Use of coumarins and carbostyrils as PLA2-inhibitors, new coumarins and carbostyrils, process for preparing the same and medicaments
BR9408244A (pt) Derivados de azabiciclo[3.2.0]heptano N-substituídos
TW261614B (no)
TR200000444T2 (tr) 3-Aril-süksinamido-hidroksamik asitler, üretim yöntemleri ve bu maddeleri içeren farmasötik terkipler.
MX9306995A (es) Derivados de acido orto-etenilfenilacetico sustituidos.
EP0653206A4 (en) ANTI-HIV ACTIVE SUBSTANCE.
PL355763A1 (en) Novel derivatives of 3-imino-1,2-dithioles, method for producing them and pharmaceutical compositions containing the same